The Chronic Neuropathic Pain market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032.
It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chronic Neuropathic Pain: An Overview
Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibers and central neurons, and affects 7–10% of the general population. Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the aging global population, increased incidence of diabetes mellitus, and improved survival from cancer after chemotherapy.
All neuropathic pain that is labeled as chronic has a history of an acute phase, that is, before the first 3 months have elapsed, a timeline agreed upon by the International Association for the Study of Pain and the WHO.
The treatment initially focuses on resolving the underlying cause. Medications used to treat neuropathic pain include over-the-counter analgesics, anticonvulsants, tricyclic antidepressants (TCAs), topical anesthetic agents, nonsteroidal anti-inflammatory drugs (NSAIDs), antiarrhythmics, narcotic analgesics, and opioids.
Chronic Neuropathic Pain Market Key Facts
According to an article by Melillo (2020), published in the American Journal of Managed Care, in France, the prevalence of chronic neuropathic pain is around 6.9%.
As per the article by Yu et al. (2020), chronic neuropathic pain is a widespread condition that affects 7–8% of the total population.
As per the article by Posso et al. (2016) titled, “Epidemiology of neuropathic pain,” a study of the German population has shown that in general 6.5% of respondents have reported pain with chronic neuropathic pain characteristics, and have reported higher intensity and more interference of pain in their daily activities as compared to individuals with chronic non-neuropathic pain.
As per DelveInsight, chronic neuropathic pain is more prevalent among females of older ages as compared to people from other age groups.
Chronic Neuropathic Pain Market
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic Neuropathic Pain market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Chronic Neuropathic Pain market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Get the Sample PDF of the Report:- https://www.delveinsight.com/sample-request/chronic-neuropathic-pain-market
Chronic Neuropathic Pain Epidemiology
The epidemiology section covers insights about the historical and current Chronic Neuropathic Pain patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Chronic Neuropathic Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Neuropathic Pain market or expected to get launched in the market during the study period. The analysis covers Chronic Neuropathic Pain market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Chronic Neuropathic Pain Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Chronic Neuropathic Pain Therapeutics Analysis
As per DelveInsight, the Chronic Neuropathic Pain market size shall grow during the forecast period owing to the launch of emerging therapies and increased patient pool in the 7MM.
Key Companies in the Chronic Neuropathic Pain Market includes:
MedinCell
Kineta
Pfizer
Algiax Pharmaceuticals
Centrexion Therapeutics
And many others.
Chronic Neuropathic Pain Therapies covered in the report include:
AP-325
CNTX-6016
Lyrica
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies: https://www.delveinsight.com/sample-request/chronic-neuropathic-pain-market
Table of Content
1. Key Insights
2. Executive Summary
3. Chronic Neuropathic Pain Competitive Intelligence Analysis
4. Chronic Neuropathic Pain Market Overview at a Glance
5. Chronic Neuropathic Pain Disease Background and Overview
6. Chronic Neuropathic Pain Patient Journey
7. Chronic Neuropathic Pain Epidemiology and Patient Population
8. Chronic Neuropathic Pain Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Neuropathic Pain Unmet Needs
10. Key Endpoints of Chronic Neuropathic Pain Treatment
11. Chronic Neuropathic Pain Marketed Products
12. Chronic Neuropathic Pain Emerging Therapies
13. Chronic Neuropathic Pain Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Neuropathic Pain Market Outlook (7 major markets)
16. Chronic Neuropathic Pain Access and Reimbursement Overview
17. KOL Views on the Chronic Neuropathic Pain Market.
18. Chronic Neuropathic Pain Market Drivers
19. Chronic Neuropathic Pain Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/chronic-neuropathic-pain-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
